Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus bevacizumab as first-line maintenance for RAS/BRAF-mutated metastatic colorectal cancer
ChiCTR2500102373Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500102373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102373.